AngioDynamics (ANGO) Tops Q1 EPS by 9c, Revenues Beat; Offers FY21 EPS/Revenue Guidance Above Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. BA
6. SPY
7. META
8. HOOD
9. INTC
10. JBLU

Go back to AngioDynamics (ANGO) Tops Q1 EPS by 9c, Revenues Beat; Offers FY21 EPS/Revenue Guidance Above Consensus

AngioDynamics Reports Fiscal 2021 First Quarter Financial Results

September 29, 2020 7:00 AM EDT

Fiscal 2021 First Quarter Highlights

Net sales of $70.2 million increased 6.3% compared to the prior-year quarter, inclusive of the previously disclosed $5.2 million order from the National Health Service (NHS) in the UK Gross margin declined 700 basis points year over year to 50.9% GAAP loss per share of $0.11 and adjusted earnings per share of $0.02 Cash and cash equivalents on August 31, 2020 were $47.9 million, compared to $54.4 million on May 31, 2020 The Company expects fiscal year 2021 net sales between $278 and $284 million and fiscal year 2021 adjusted earnings per share between $0.00 and $0.05... More